[go: up one dir, main page]

PE20090772A1 - Derivados de bencimidazol - Google Patents

Derivados de bencimidazol

Info

Publication number
PE20090772A1
PE20090772A1 PE2008001105A PE2008001105A PE20090772A1 PE 20090772 A1 PE20090772 A1 PE 20090772A1 PE 2008001105 A PE2008001105 A PE 2008001105A PE 2008001105 A PE2008001105 A PE 2008001105A PE 20090772 A1 PE20090772 A1 PE 20090772A1
Authority
PE
Peru
Prior art keywords
methylpiperidin
alkyl
compounds
benzimidazol
halo
Prior art date
Application number
PE2008001105A
Other languages
English (en)
Inventor
Christopher Scott Jones
GRECA Susan LA
Qifang Li
Lawrence Alan Reifer
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20090772A1 publication Critical patent/PE20090772A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE BENCIMIDAZOL DE FORMULA (IIa) DONDE R1 ES HALO, ALQUILO(C1-C6), ALCOXI(C1-C6), CF3, ENTRE OTROS; R2 Y R4 SON CADA UNO H O ALQUILO(C1-C6); R3B ES H, ALQUILO(C1-C6), (CH2)t-ARILO(C6-C12), ENTRE OTROS, EN DONDE t ES DE 0 A 2; R10 ES (CH2)t-ARILO(C6-C12) O (CH2)t-HETEROCICLILO DE 4 A 14 MIEMBROS OPCIONALMENTE SUSTITUIDOS CON CN, HALO, CF3, OCF3, ENTRE OTROS; n ES DE 0 A 4. SON COMPUESTOS PREFERIDOS: 1-[(2R,4R)-2-(1H-BENZIMIDAZOL-2-IL)-1-METILPIPERIDIN-4-IL]-3-(4-CIANOFENIL)UREA, 1-[(2R,4R)-2-(1H-BENZIMIDAZOL-2-IL)-1-METILPIPERIDIN-4-IL]-3-(4-CLOROFENILO), 1-[(2R,4R)-2-(1H-BENZIMIDAZOL-2-IL)-1-METILPIPERIDIN-4-IL]-3-(6-FLUOROPIRIDIN-3-IL)UREA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE CRECIMIENTO CELULAR ANORMAL TAL COMO CANCER
PE2008001105A 2007-06-29 2008-06-27 Derivados de bencimidazol PE20090772A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94728707P 2007-06-29 2007-06-29
US4164508P 2008-04-02 2008-04-02

Publications (1)

Publication Number Publication Date
PE20090772A1 true PE20090772A1 (es) 2009-06-24

Family

ID=40161351

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2008001105A PE20090772A1 (es) 2007-06-29 2008-06-27 Derivados de bencimidazol
PE2012000473A PE20121010A1 (es) 2007-06-29 2008-06-27 Derivados de bencimidazol

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2012000473A PE20121010A1 (es) 2007-06-29 2008-06-27 Derivados de bencimidazol

Country Status (45)

Country Link
US (2) US8148401B2 (es)
EP (1) EP2170860B9 (es)
JP (2) JP4567099B2 (es)
KR (1) KR101143246B1 (es)
CN (1) CN101687841B (es)
AP (1) AP2377A (es)
AR (1) AR067346A1 (es)
AU (1) AU2008272641B2 (es)
BR (1) BRPI0813412B8 (es)
CA (1) CA2690953C (es)
CL (1) CL2008001922A1 (es)
CO (1) CO6160232A2 (es)
CR (1) CR11150A (es)
CU (1) CU23847B1 (es)
CY (2) CY1118650T1 (es)
DK (1) DK2170860T5 (es)
DO (1) DOP2009000278A (es)
EA (1) EA016888B1 (es)
EC (1) ECSP099803A (es)
ES (1) ES2609258T3 (es)
FR (1) FR20C1038I2 (es)
GE (1) GEP20125702B (es)
GT (1) GT200900328A (es)
HN (1) HN2008000974A (es)
HR (1) HRP20161562T2 (es)
HU (2) HUE030052T4 (es)
IL (1) IL202420A (es)
LT (2) LT2170860T (es)
MA (1) MA31466B1 (es)
ME (1) ME00962B (es)
MY (1) MY148636A (es)
NI (1) NI200900219A (es)
NL (1) NL301057I2 (es)
NO (1) NO2020027I1 (es)
NZ (1) NZ581889A (es)
PA (1) PA8785401A1 (es)
PE (2) PE20090772A1 (es)
PL (1) PL2170860T3 (es)
PT (1) PT2170860T (es)
RS (1) RS55395B9 (es)
SI (1) SI2170860T1 (es)
TN (1) TN2009000544A1 (es)
TW (1) TWI371451B (es)
UY (1) UY31164A1 (es)
WO (1) WO2009004427A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009004427A2 (en) * 2007-06-29 2009-01-08 Pfizer Inc. Benzimidazole derivatives
EP2330894B8 (en) 2008-09-03 2017-04-19 BioMarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
MX2011013294A (es) * 2009-06-11 2012-01-12 Siena Biotech Spa Antagonistas de la trayectoria de hedgehog y aplicaciones terapeuticas de los mismos.
NZ598749A (en) 2009-08-26 2013-01-25 Takeda Pharmaceutical Fused heterocyclic ring derivative and use thereof
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
EP2630134B9 (en) 2010-10-20 2018-04-18 Pfizer Inc Pyridine-2- derivatives as smoothened receptor modulators
JP5452459B2 (ja) 2010-12-16 2014-03-26 株式会社Nttドコモ ホーム基地局及びハンドオーバ方法
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
CA3061239A1 (en) 2011-02-28 2012-09-07 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
EP2684167B1 (en) 2011-03-08 2020-09-09 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
FR2980477B1 (fr) 2011-09-23 2013-10-18 Centre Nat Rech Scient Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
ES2612934T3 (es) 2011-09-26 2017-05-19 Merck Patent Gmbh Compuestos de piperidin bencilo como antagonista del receptor del ácido lisofosfatídico (LPA)
US20150150869A1 (en) 2012-06-20 2015-06-04 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
EP2922544B1 (en) 2012-11-21 2018-08-01 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
CN105121415B (zh) 2013-03-15 2018-10-12 生物马林药物股份有限公司 Hdac抑制剂
EP2996689A1 (en) 2013-04-17 2016-03-23 Albert-Ludwigs-Universität Freiburg Compounds for use as bromodomain inhibitors
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
GB2519344A (en) * 2013-10-18 2015-04-22 Redx Pharma Ltd Compounds
AU2014342269B2 (en) 2013-10-30 2020-02-27 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
DK3666768T3 (da) 2015-04-24 2022-06-27 Pfizer F r e m g a n g s m å d e t i l f r e m s t i l l i n g a f e n k r y s t a l l i n s k f o r m a f 1-((2R,4R)-2-(1H-benzo[D]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)ureamaleat; krystallinsk form af 1-((2R,4R)-2-(1H-benzo[D]imidazol-2-YL)-1-methylpiperidin-4-YL)-3-(4-cyanophenyl)ure
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
JP2020164722A (ja) * 2019-03-29 2020-10-08 デクセリアルズ株式会社 接着剤組成物
US20230107634A1 (en) 2020-01-28 2023-04-06 Teva Pharmaceuticals International Gmbh Processes for the preparation of glasdegib and salt thereof and solid state forms of glasdegib maleate and process for preparation thereof
CN113248475B (zh) * 2020-02-11 2023-03-17 中国科学院上海药物研究所 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途
WO2021191278A1 (en) 2020-03-26 2021-09-30 Lek Pharmaceuticals D.D. Dimaleate form of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea
WO2021261601A1 (ja) 2020-06-26 2021-12-30 ラクオリア創薬株式会社 レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬
WO2023002362A1 (en) 2021-07-22 2023-01-26 Pfizer Inc. Treatment of hematological malignancy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4658473B2 (ja) 2001-07-27 2011-03-23 キュリス,インコーポレイテッド ヘッジホッグシグナル伝達経路メディエーター、それに関連した組成物及び利用
WO2003048154A1 (en) * 2001-12-04 2003-06-12 Actelion Pharmaceuticals Ltd 4-(piperidyl- and pyrrolidyl-alkyl-ureido) -quinolines as urotensin ii receptor antagonists
TW200304820A (en) 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
WO2004035549A1 (en) 2002-10-17 2004-04-29 Amgen Inc. Benzimidazole derivatives and their use as vanilloid receptor ligands
WO2005042495A1 (en) 2003-10-21 2005-05-12 Imclone Systems Incorporated (benzimidazol-2-yl)-phenyl-phenyl-urea compounds and methods for inhibiting heparanase activity
US7309716B2 (en) 2003-10-28 2007-12-18 Vertex Pharmaceuticals Incorporated Benzimidazoles useful as modulators of ion channels
EP1807074B1 (en) * 2004-11-03 2013-10-23 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
DE102005012875B4 (de) 2005-03-19 2006-11-16 Sanofi-Aventis Deutschland Gmbh Verwendung von Amino substituierten 8-N-Benzimidazolen
WO2006124780A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
WO2008064830A1 (en) 2006-11-27 2008-06-05 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their pharmaceutical uses
EP2121626A1 (en) 2006-12-15 2009-11-25 Pfizer Products Inc. Benzimidazole derivatives
WO2009004427A2 (en) 2007-06-29 2009-01-08 Pfizer Inc. Benzimidazole derivatives
US20120094974A1 (en) 2008-06-17 2012-04-19 Wei Chen Smoothened receptor modulators
EP2328871B1 (en) 2008-08-25 2020-04-01 Novartis AG Hedgehog pathway modulators

Also Published As

Publication number Publication date
AU2008272641A1 (en) 2009-01-08
CY2020028I2 (el) 2020-11-25
PA8785401A1 (es) 2009-01-23
MA31466B1 (fr) 2010-06-01
ECSP099803A (es) 2010-01-29
EP2170860A2 (en) 2010-04-07
EA016888B1 (ru) 2012-08-30
US20090005416A1 (en) 2009-01-01
LTPA2020528I1 (lt) 2020-09-25
CA2690953A1 (en) 2009-01-08
HUE030052T2 (hu) 2017-04-28
ME00962B (me) 2012-06-20
GEP20125702B (en) 2012-12-10
IL202420A (en) 2014-05-28
LT2170860T (lt) 2017-01-10
HN2008000974A (es) 2011-01-24
HK1139658A1 (en) 2010-09-24
KR101143246B1 (ko) 2012-05-18
HUS2000031I1 (hu) 2020-09-28
CL2008001922A1 (es) 2009-01-02
CY1118650T1 (el) 2017-07-12
SI2170860T1 (sl) 2017-01-31
NL301057I2 (nl) 2020-09-10
CN101687841B (zh) 2013-07-10
RS55395B1 (sr) 2017-04-28
TW200911792A (en) 2009-03-16
EP2170860B1 (en) 2016-11-02
CU20090225A7 (es) 2012-02-15
CY2020028I1 (el) 2020-11-25
FR20C1038I2 (fr) 2021-08-13
CN101687841A (zh) 2010-03-31
TN2009000544A1 (fr) 2011-03-31
IL202420A0 (en) 2010-06-30
BRPI0813412B8 (pt) 2021-05-25
EP2170860B9 (en) 2017-02-22
WO2009004427A3 (en) 2009-06-04
US20120157495A1 (en) 2012-06-21
AU2008272641B2 (en) 2013-08-29
HRP20161562T2 (hr) 2017-04-21
PE20121010A1 (es) 2012-08-06
DK2170860T3 (en) 2017-01-09
JP4567099B2 (ja) 2010-10-20
UY31164A1 (es) 2009-01-30
ES2609258T3 (es) 2017-04-19
DK2170860T5 (en) 2017-03-20
AP2009005089A0 (en) 2009-12-31
CR11150A (es) 2010-02-08
JP2010280693A (ja) 2010-12-16
CU23847B1 (es) 2012-10-15
HRP20161562T1 (hr) 2016-12-30
TWI371451B (en) 2012-09-01
PL2170860T3 (pl) 2017-05-31
CA2690953C (en) 2012-10-02
HUE030052T4 (en) 2017-06-28
LTC2170860I2 (lt) 2022-03-10
DOP2009000278A (es) 2009-12-31
BRPI0813412B1 (pt) 2020-01-21
PT2170860T (pt) 2017-01-04
KR20100028120A (ko) 2010-03-11
RS55395B9 (sr) 2020-01-31
AP2377A (en) 2012-03-07
GT200900328A (es) 2011-08-29
FR20C1038I1 (es) 2020-10-02
WO2009004427A2 (en) 2009-01-08
EA200971104A1 (ru) 2010-06-30
NL301057I1 (nl) 2020-07-22
NZ581889A (en) 2011-05-27
US8148401B2 (en) 2012-04-03
NI200900219A (es) 2010-03-11
US8431597B2 (en) 2013-04-30
CO6160232A2 (es) 2010-05-20
MY148636A (en) 2013-05-15
NO2020027I1 (no) 2020-08-11
JP2010531869A (ja) 2010-09-30
BRPI0813412A2 (pt) 2014-12-30
AR067346A1 (es) 2009-10-07

Similar Documents

Publication Publication Date Title
PE20090772A1 (es) Derivados de bencimidazol
PE20211700A1 (es) Compuesto heterociclico y su uso
PE20090952A1 (es) Compuestos de pirazol moduladores de raf
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20110367A1 (es) DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
PE20091573A1 (es) Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
PE20080418A1 (es) Compuestos y composiciones como moduladores de la via de hedgehog
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
PE20090649A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20090890A1 (es) Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c
PE20081882A1 (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa
PE20190175A1 (es) Compuestos de pirrolotriazina como inhibidores de tam
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20140185A1 (es) Derivados de heteroarilpiperidina y piperazina como fungicidas
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20070189A1 (es) COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA
CU23813A3 (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20081753A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal
PE20142185A1 (es) Pirrolidina-2-carboxamidas sustituidas
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
PE20090435A1 (es) Inhibidores de tetrahidropiranocromeno de gamma secretasa
PE20110433A1 (es) Antagonistas de la via hedgehog de ftalazina disustituida

Legal Events

Date Code Title Description
FG Grant, registration